# OnCo record paper-keynote-017-j-immunother-cancer-2021-update (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-017-j-immunother-cancer-2021-update/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-017-j-immunother-cancer-2021-update" ;
  schema:name "Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma"@en ;
  schema:description "Later report from the KEYNOTE-017 trial registered as NCT02267603, in Journal for ImmunoTherapy of Cancer (2021); its title describes an updated or longer-term analysis."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-017-j-immunother-cancer-2021-update/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1136/jitc-2021-002478>, <https://pubmed.ncbi.nlm.nih.gov/33879601/>, <https://europepmc.org/article/MED/33879601>, <https://clinicaltrials.gov/study/NCT02267603> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1136/jitc-2021-002478> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Nghiem P, Bhatia S, Lipson EJ, et al." ;
  onco:trials <https://onco.cc/trials/keynote-017/> ;
  onco:journals <https://onco.cc/journals/jitc/> .